Edit
Unknown Domain
http://www.vaxin.com/Last activity: 02.04.2015
Active - Reference to Altimmune, Inc.
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B, and conjugated immunostimulants for the treatment of cancer. In addition, we are developing intranasal vaccine & therapeutic candidates for anthrax, influenza and COVID-19.
Location: United States
Employees: 1-10
Total raised: $8M
Founded date: 1997
Investors 1
| Date | Name | Website |
| - | Redmont Ca... | redmontcap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.04.2015 | - | $8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 02.04.2015 | Biotech firm Vaxin raises $8M [Startup Roundup] | WHO’S GETTING FUNDED? Gaithersburg, Md.-based Vaxin, a biotech company focused on developing “novel vaccines,” raised $8 million, the company’s president and CEO Bill Enright told Technical.ly DC. That’s out of a projected $16 million post-... |
| - | Vaxin enters definitive agreement to acquire Immune Targeting Systems (ITS); Secures $16m in new financing | Gaithersburg, Maryland – February 17, 2015 – Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has entered into a definitive agreement to acquire Imm... |
| - | VAXIN CHANGES COMPANY NAME TO ALTIMMUNE | Move Reflects Company’s Expansion beyond Vaccines to Include Immunotherapeutics Gaithersburg, Maryland – Sept 1st 2015- Vaxin Inc., a clinical stage immunotherapy and vaccine company, today announced that it has changed its corporate name ... |
| - | VAXIN CEO TO PRESENT AT FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE | Gaithersburg, Maryland – March 17, 2015 – Vaxin, a clinical stage vaccine development company today announced that CEO Bill Enright will present at the Future Leaders in the Biotech Industry Conference this Friday in New York City. Now in i... |
| - | Vaxin First-in-Man Phase I Clinical Trial Initiated in Chronically Infected Hepatitis B Patients | Gaithersburg, Maryland – July 27 2015. Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell™ (FP-02.2), the company’s immunothe... |
| - | VAXIN STRENGTHENS INTELLECTUAL PROPERTY PORTFOLIO | Gaithersburg, Maryland – July 21 2015- Vaxin Inc. today announced that it has added key patents to its expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company confirmed that the United State... |